Stroke study seeks to personalize statin therapy

NCT ID NCT07344610

Knowledge-focused Sponsor: General Hospital of Shenyang Military Region Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is observing 800 people who recently had an ischemic stroke or have significant artery narrowing. All are taking high doses of statins (atorvastatin or rosuvastatin) for at least a week. Researchers want to see how much their cholesterol drops and what factors influence that drop, to help guide future personalized treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: atorvastatin or rosuvastatin
What this could lead to: If successful, this could help doctors tailor statin doses to individual patients after a stroke, potentially improving prevention of future strokes.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary widely among patients and may not apply to all stroke types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with ischemic stroke (within 14 days of onset) confirmed by cranial CT/MRI, or imaging-confirmed intracranial/extracranial atherosclerotic stenosis (stenosis rate ≥ 50%);

Ages: 18 years and older
Sex: Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years; * Diagnosis of ischemic stroke (within 14 days of onset) confirmed by cranial CT/MRI; or imaging-confirmed intracranial/extracranial atherosclerotic stenosis (stenosis rate ≥ 50%); * Intensive statin therapy (e.g., atorvastatin 40-80 mg/day or rosuvastatin 20 mg/day) initiated within 24 hours of admission, with a planned continuous application for at least one week; * Signed informed consent form. Exclusion Criteria: * Use of statin therapy within 1 week prior to admission; * Receiving other lipid-lowering treatments; * Presence of other serious comorbidities (e.g., malignant tumors, end-stage heart failure) with an expected survival of \<1 year; * Pregnant or lactating women; * Participation in other drug clinical trials within 3 months; * Other conditions deemed unsuitable by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Stroke study seeks to personalize statin therapy

What the study statuses mean